Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer

Future Oncology
Lakshmikirupa SundaresanSuvro Chatterjee

Abstract

To understand why thalidomide and lenalidomide exhibit different responses in metastatic prostate cancer (mPCa) treatment. We analyzed the perturbation signatures of thalidomide, lenalidomide, flutamide treated mPCa cell line from Library of Integrated Network-based Cellular Signatures database and transcriptome of docetaxel-treated mPCa patients. Flutamide and docetaxel downregulated 'Steroid Biosynthesis', 'Cell cycle' and PCa specific transcription factor networks. Thalidomide inhibited 'Cell cycle' and 'E2F network', possibly accounting for its synergistic effects with docetaxel. Conversely, lenalidomide promoted 'Cell cycle' and 'Cholesterol biosynthesis'. Hence, we propose that lenalidomide upregulates cholesterol synthesis followed by enhanced rate of cell cycle, thereby nurturing a hyperproliferative tumor microenvironment. In summary, this study offers a possible explanation for the differential outcomes in the treatment of mPCa with thalidomide and lenalidomide.

References

Oct 20, 1993·Journal of the National Cancer Institute·N M NavoneC J Conti
Apr 1, 1996·Molecular and Cellular Biology·J KarlsederE Wintersberger
Aug 26, 1998·The Journal of Clinical Endocrinology and Metabolism·E Diamanti-KandarakisA J Duleba
Jan 16, 2002·Oncogene·Katerina V GurovaAndrei V Gudkov
Jan 19, 2002·Genes & Development·Bing RenBrian David Dynlacht
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William L DahutWilliam D Figg
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Feb 24, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eleni EfstathiouChristopher J Logothetis
Nov 18, 2008·Investigational New Drugs·Sharon L SanbornMatthew M Cooney
May 20, 2009·Journal of Clinical Pharmacology·William L DahutWilliam D Figg
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yang-Min NingWilliam L Dahut
Apr 20, 2010·Lancet·Howard I ScherUNKNOWN Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Jun 30, 2011·Endocrine-related Cancer·Changmeng Cai, Steven P Balk
Oct 15, 2011·International Journal of Clinical Practice·M KirbyE D Crawford
May 11, 2012·Nucleic Acids Research·Daniel Tabas-MadridAlberto Pascual-Montano
Jul 25, 2012·Current Opinion in Pharmacology·Kristine PeltonKeith R Solomon
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Nov 8, 2012·Nature Reviews. Urology·Lara K BoydYong-Jie Lu
Jun 29, 2013·Seminars in Oncology·Randy Schrecengost, Karen E Knudsen
Oct 7, 2015·International Journal of Cardiology·Milla Machado FumianFernanda Carla Ferreira de Brito
May 5, 2016·Nucleic Acids Research·Maxim V KuleshovAvi Ma'ayan
Nov 1, 2016·CPT: Pharmacometrics & Systems Pharmacology·L Cheng, L Li
Jan 29, 2017·Cancer Research·Mahmoud A AlfaqihStephen J Freedland

❮ Previous
Next ❯

Citations

Sep 23, 2020·In Vitro Cellular & Developmental Biology. Animal·Pavitra KumarSuvro Chatterjee

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE51005

Methods Mentioned

BETA
biopsies

Software Mentioned

Topcluster
Enrichr
GeneCodis
Panther
ChEA
IPA
Toppcluster
Genelinker
Ingenuity analysis
KEGG

Related Concepts

Related Feeds

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

© 2022 Meta ULC. All rights reserved